Streetbeat News

Price Targets

RITM

Wedbush analyst Jay McCanless has reiterated an Outperform rating on Rithm Capital (NYSE:RITM) and maintained a $12 price target.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 1:10 pm

CELH

Wedbush analyst Gerald Pascarelli has reiterated an Outperform rating on Celsius Holdings (NASDAQ:CELH) and maintained a price target of $155.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 1:10 pm

UTHR

Wedbush analyst Liana Moussatos has maintained an 'Outperform' rating on United Therapeutics (NASDAQ:UTHR) and raised the price target from $305 to $307.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 1:09 pm

ADNT

Barclays analyst Dan Levy maintains an Overweight rating on Adient (NYSE:ADNT) and raises the price target from $50 to $54.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:09 pm

TRIN

Oppenheimer analyst Mitchel Penn maintains an Outperform rating on Trinity Cap (NASDAQ:TRIN) and raises the price target from $13 to $15.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 1:09 pm

RVLV

Revolve Gr (NYSE:RVLV) has received mixed analyst ratings in the last quarter, with 3 bullish, 1 somewhat bullish, 2 indifferent, and 1 somewhat bearish. The average 12-month price target for the stock is $20.86, representing an 11.61% decrease from the previous average price target of $23.60.

Portfolio Pulse from Benzinga Insights

August 04, 2023 | 1:09 pm

PERI

Oppenheimer analyst Jason Helfstein maintains an Outperform rating on Perion Network (NASDAQ:PERI) and raises the price target from $44 to $45.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 1:09 pm

GTHX

Wedbush analyst David Nierengarten has reiterated an Outperform rating on G1 Therapeutics (NASDAQ:GTHX) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 1:09 pm

SHOO

Citigroup analyst Steven Madden maintains a Buy rating on Steven Madden (NASDAQ:SHOO) and raises the price target from $40 to $41.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:08 pm

ALLO

Oppenheimer analyst Mark Breidenbach has reiterated his 'Outperform' rating on Allogene Therapeutics (NASDAQ:ALLO), maintaining a price target of $28.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 1:08 pm